Infusion Safety Pharmacology Services

Browse infusion capabilities from the catalog

• Anti-tussive Citric Acid-Induced Cough

  Discovery

• Asthma: House Dust mite – Chronic model

  Discovery

• Asthma: Ovalbumin sensitization and challenge

  Discovery

• Cannulation: Bile duct (BDC studies)

  ADME

• Bronchoconstriction models for LABA, LAMA & MABAs

  Discovery

• Cannulation: Vascular

  Animal, Radiolabeled, ADME

• Chlorine Induced Lung Injury

  Discovery

• COPD: Acute Tobacco Smoke Model (5, 12 or 17 Day)

  Discovery

• COPD: Human Neutrophil Elastase Lung Hemorrhage Model

  Discovery

• COPD: LPS + fMLP PK/PD model – Neutrophil Elastase Targets

  Discovery

• COPD: LPS neutrophil chemotaxis model (inhaled)

  Discovery

• COPD: LPS neutrophil chemotaxis model (systemic)

  Discovery

• ePPND and EFD NHP studies

  DART

• Flu Model: H1N1 influenza lung infection model – viral COPD exacerbation

  Discovery

• Interstitial Pulmonary Fibrosis (IPF) Bleomycin-Induced Lung Fibrosis

  Discovery

• In vivo pharmacokinetics (PK)

  Metabolism

• iPRECIO® pump

  Pharmacology (Safety)

• Maximum tolerable dose (MTD) studies

  Range-finding

• Methicillin-resistant Staphylococcus aureus (MRSA) neutropenic thigh infection model

  Discovery

• Model: Cystic Fibrosis: Pseudomonas aeruginosa lung injury

  Discovery

• Model of Allergic Bronchopulmonary Aspergillosis (ABPA) in Mice

  Discovery

• Model of Invasive Aspergillosis in Immunocompromised Mice

  Discovery

• Monocrotaline induced Pulmonary Hypertension (PAH)

  Discovery

• Quantitative whole body autoradiography (QWBA) studies

  Radiolabeled, hAME

• Respiratory Syncytial Virus (RSV) lung infection

  Discovery

• Toxicity studies: Acute (single dose)

  Acute

• Toxicity studies: Chronic

  Chronic (26-52 wk)

• Toxicity studies: Subchronic

  Subchronic (0-26 wk)

• Toxicity study: Juvenile (NHP)

  DART